<DOC>
	<DOCNO>NCT01466803</DOCNO>
	<brief_summary>Variability drug response due either pharmacokinetic pharmacodynamic factor . The reason people differ pharmacokinetics pharmacodynamics manifold include , e.g. , genetic factor , disease , age concomitantly administer drug . Oxidation reaction dominant metabolism drug cytochrome P-450 enzyme ( CYP ) recognize chief contributor ( Guengerich 1992 ) . We previously show drug interaction mediate inhibition CYP enzymes may major clinical significance ( Olkkola et al . 1993 ; Olkkola et al . 1994 ; Varhe et al . 1994 ; Olkkola et al . 1999 ; Palkama et al . 1999 ; Jokinen et al . 2000 ) . Buprenorphine undergoes extensive first-pass metabolism low oral bioavailability 15 % ( Cone et al . 1984 ) . Bioavailability follow sublingual administration buprenorphine high , 50-60 % ( Nath et al . 1999 ) . After high sublingual dos buprenorphine ( 8-24 mg ) , peak plasma concentration reach 1 hour ( McAleer et al . 2003 , Ciraulo et al . 2006 ) low sublingual dos ( 0.4 mg ) reach approximately 3 h ( Billingham 1981 ) . Approximately two-thirds buprenorphine dose excrete unchanged , rest metabolize liver intestinal wall . N-dealkylation buprenorphine mainly via CYP3A also CYP2C8 yield norbuprenorphine , glucuronidation yield buprenorphine-3-glucuronide ( Cone et al . 984 ) . Norbuprenorphine excrete urine subsequent conjugation . 80-90 % buprenorphine excrete biliary system enterohepatic circulation ( Brewster et al . 1984 ) Although interaction study high-dose buprenorphine antiretrovirals conduct ( McCance-Katz EF et al . 2007 ) , effect CYP3A inhibitor pharmacokinetics low-dose buprenorphine unknown . Because use buprenorphine pain management increase introduction transdermal buprenorphin patch market , clinically relevant study quantify possible interaction buprenorphine inhibitor CYP3A-mediated metabolism voriconazole . This study aim examine possible interaction oral buprenorphine voriconazole . Twelve male female adult non-smoking subject age 18-40 year body weight within ±15 % ideal weight height recruit study . The subject submit physical examination , determination previous present chronic disease , comprehensive laboratory test ascertain good health . The subject fill modify Finnish version Abuse Questions ( Michna et al . 2004 ) ass vulnerability opioid abuse . Laboratory screen include CBC ( include hemoglobin , hematocrit , differential WBC , platelet count ) , SGOT , SGPT , alkaline phosphatase , BUN creatinine , woman pregnancy test . Urine screen glucose , proteins drug addiction potential . Blood pressure sit position must within normal limit . Base line ECG must normal . Placebo voriconazole always ingest food , except first dose day 5 . On day 5 , challenge dose 0.2 3.6. mg oral buprenorphine ( Temgesic , Schering-Plough ) administer 11.00 , i.e . 1 h last dose placebo voriconazole . The dose 3.6 mg placebo 0.2 mg voriconazole . If necessary , naloxone ( Naloxone B. Braun , Braun ) give sufficient dos counteract severe adverse effect buprenorphine . For nausea vomiting , intravenous tropisetron use , need . The volunteer fast least 8 h administration buprenorphine standard meal 4 h 8 h afterwards . Ingestion alcohol , coffee , tea , cola , energydrinks grapefruit juice allow test day , smoke permit . The interval study phase four week .</brief_summary>
	<brief_title>Effects Voriconazole Pharmacokinetics Pharmacodynamics Oral Buprenorphine : A Two-phase Cross-over Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Healthy volunteer Age 1840 Body weight within ±15 % ideal weight height A previous history intolerance study drug related compound additives Concomitant drug therapy kind least 14 day prior study Existing recent significant disease History hematological , endocrine , metabolic gastrointestinal disease , include gut motility disorder History asthma kind drug allergy Previous present alcoholism , drug abuse , psychological emotional problem likely invalidate inform consent , limit ability subject comply protocol requirement A positive test result urine toxicology A `` yes '' answer one Abuse Questions Pregnancy nurse Donation blood 4 week prior study Special diet life style condition would compromise condition study interpretation result Participation study involve investigational market drug product concomitantly within one month prior entry study Smoking one month start study whole study period Any history coagulation abnormality , also first degree relative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>Vorikonazole</keyword>
	<keyword>Interactions</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Voriconazole</keyword>
</DOC>